ARROWHEAD PHARMACEUTICALS IN (ARWR)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Noteworthy Wednesday Option Activity: ARWR, MARA, KSS

ARWR Crosses Above Key Moving Average Level

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta

The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets.

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome

First Week of ARWR June 2025 Options Trading

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Becomes Oversold (ARWR)

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Interesting ARWR Put And Call Options For October 18th

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies

ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q3 2024

ARWR stock results show that Arrowhead Pharma missed analyst estimates for earnings per share the third quarter of 2024.

ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q3 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arrowhead Pharma (NASDAQ:ARWR) just reported results for the third quarter of 2...

Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results

Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

ARWR Crosses Above Key Moving Average Level